Ampersand is a company that is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. They have developed the Address, Navigate, Design (AND)™ Platform to create next-generation modular medicines that work precisely where needed in the body and nowhere else. Their AND-Body™ Therapeutics combine elements that locate their intended target with elements that actuate biology to treat disease.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

BIO:AMPERSAND

Ampersand Biomedicines

Analysis Not Available